Newly discovered prostate cancer biomarkers may help detect aggressive cases of the disease and help treat this type of cancer in a timely manner. Prostate cancer begins in the male reproductive system. The prostate is located below the bladder and in front of the rectum, taking up space the size of a walnut. Any man is at risk of developing prostate cancer, but some risk factors can be age and weight � men who are overweight and over the age of 50 have a much higher risk of prostate cancer. Some symptoms of early stage prostate cancer may be a dull pain in the lower part of the pelvis, frequent urination, blood or pain during urination and ejaculation. With these symptoms, it is recommended to immediately contact a doctor and conduct tests. New biological markers discovered by scientists can determine the cancer and its properties – how aggressive it is and what would be the appropriate treatment for it. Compared to other indicators of prostate cancer, these 3 biomarkers serve to establish the extent of the disease much more accurately. According to the World Cancer Research Fund, the second most common cancer in men is prostate cancer, after skin cancer. In 2020, more than 1 million cases of the disease were diagnosed. The discovery of new biological indicators with the best possible accuracy for detecting prostate cancer is a breakthrough in the treatment and diagnosis of the disease. Prostate cancer is a disease that can be in the body for years without the sufferer knowing about its existence. The possibility of the earliest possible detection will allow the most correct and successful treatment, which will remove the malignant tumor. In mild cases of prostate cancer, the tumor is removed by surgery or radiotherapy, but if the disease progresses, other measures such as chemotherapy are required, which comes with a number of side effects. The scientists who discovered the biomarkers plan to develop a new technology that will take advantage of our knowledge of them for early diagnosis of prostate cancer. The paper was presented to Cancers. References: University of South Australia. (2023, July 19) New prostate cancer biomarkers provide hope to millions of men. Bates, M. (2023, June 16) Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1. Retrieved 2023, July 19 from https://www.mdpi.com/2072-6694/15/12/3215